Gül Fatih Cem, Güngör Kobat Sabiha, Çelik Fatih, Aydin Süleyman, Akkoç Ramazan Fazil
Ophthalmology Clinic, Elazığ City Hospital, Elazig 23200, Turkey.
Department of Biochemistry, Firat University, Elazig 23119, Turkey.
Int J Ophthalmol. 2022 Mar 18;15(3):453-460. doi: 10.18240/ijo.2022.03.13. eCollection 2022.
To evaluate plasma and aqueous levels of adiponutrin and pannexin 1 in patients with and without diabetic retinopathy.
The study included three age and gender-matched groups of 20 cataract patients with no diabetes or additional disease (Group C), 20 cataract patients with diabetes and no retinopathy (Group DM+C), and 20 cataract patients with diabetic retinopathy (Group DR+C). All the patients were examined with respect to body mass index (BMI), fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profile. Phacoemulsification and intraocular lens (Phaco+IOL) implantation were performed to all patients in all the groups, and aqueous samples were taken during the operation. The plasma and aqueous adiponutrin and pannexin 1 levels were analyzed using enzyme-linked immunosorbent assays.
A statistically significant difference was determined between the groups with respect to BMI, fasting plasma glucose, and HbA1c levels (<0.05 for all parameters tested). The plasma adiponutrin levels of Group DR+C were statistically significantly lower than those of Group C and Group DM+C (<0.001, =0.004). No statistically significant difference was determined in the aqueous adiponutrin levels in three groups. The plasma pannexin 1 levels of Groups DM+C and DR+C were statistically significantly lower than those of Group C (both =0.001). The aqueous pannexin 1 levels of Group DR+C were statistically significantly higher than those of Group C and Group DM+C (=0.001, <0.001).
Adiponutrin and pannexin 1, which play an important role in the pathophysiology of diabetes and obesity, and have a regulatory role in hyperglycemia and insulin resistance. The measurement of adiponutrin and pannexin 1 levels may support clinicians in determining the risk of DR development.
评估患有和未患有糖尿病性视网膜病变患者的血浆和房水中脂肪营养蛋白及泛连接蛋白1的水平。
该研究纳入了三组年龄和性别匹配的患者,每组20例。分别为无糖尿病或其他疾病的白内障患者(C组)、患有糖尿病但无视网膜病变的白内障患者(糖尿病+白内障组,DM+C组)以及患有糖尿病性视网膜病变的白内障患者(糖尿病性视网膜病变+白内障组,DR+C组)。对所有患者进行体重指数(BMI)、空腹血糖、糖化血红蛋白(HbA1c)和血脂谱检查。所有组的患者均接受了超声乳化白内障吸除术和人工晶状体(Phaco+IOL)植入术,并在手术过程中采集房水样本。采用酶联免疫吸附测定法分析血浆和房水中脂肪营养蛋白及泛连接蛋白1的水平。
在BMI、空腹血糖和HbA1c水平方面,各组之间存在统计学显著差异(所有检测参数均<0.05)。DR+C组的血浆脂肪营养蛋白水平显著低于C组和DM+C组(<0.001,=0.004)。三组房水中脂肪营养蛋白水平无统计学显著差异。DM+C组和DR+C组的血浆泛连接蛋白1水平显著低于C组(均为=0.001)。DR+C组的房水泛连接蛋白1水平显著高于C组和DM+C组(=0.001,<0.001)。
脂肪营养蛋白和泛连接蛋白1在糖尿病和肥胖的病理生理过程中起重要作用,对高血糖和胰岛素抵抗具有调节作用。检测脂肪营养蛋白和泛连接蛋白1水平可能有助于临床医生确定糖尿病性视网膜病变发生的风险。